“At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures,” the company said in a
According to Anavex, the data assumes significance, as the current treatments are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing.
During the study, the drug was well tolerated, and no adverse events were reported. Anavex’
"We are encouraged, however, we should be reminded that these endpoints are exploratory and need to be confirmed in a larger study, for which planning is underway," said Christopher Missling, president and CEO of Anavex.
Shares of Anavex closed Monday’s trading at $3.29. In the pre-market hours Tuesday, the stock climbed 20 percent to $3.96.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.